Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

ADVENTRX Presents Data at the 2008 American Association for Cancer Research

Annual Meeting

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that it presented pharmacokinetic data from its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) at the 2008 American Association for Cancer Research (AACR) Annual Meeting. The poster presentation, entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," was presented by Joachim P.H. Schupp, M.D., Vice President of Medical Affairs, on April 13.

"ANX-530 is a near term value-driver for ADVENTRX and we are excited to have met the primary endpoint in this registrational trial," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "We are preparing our New Drug Application (NDA) for ANX-530, which we anticipate submitting before the end of this year. ANX-530 could be our first commercially available oncology product and, if approved by the FDA within its 10 month review goal, may generate revenues for the company towards the end of 2009."

The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530 and Navelbine. Determining the safety of a single dose of ANX-530 was a secondary objective. In the first week, patients were dosed with either ANX-530 or Navelbine, and after a washout period, were dosed with the opposite drug during the second week of treatment.

Pharmacokinetic equivalence was demonstrated by a statistic
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... for Progress MADISON, Wis. Members of the ... story of an emerging trend in the corporate world ... , ,Lori Silverman, owner of the consulting firm Partners ... Critical Shift, explained how simply following a story arc ...
... MADISON, Wis. A nurse keys a 10-milliliter-per-hour dose ... makes a simple mistake, accidentally keying in an overdose ... to receive 25 ml of a different drug, but ... like these occur every day in hospitals across the ...
... Sonic Foundry, a provider of rich-media systems and software, ... the company has announced. , ,Sonic Foundry and media ... power Courtroom Connect's new Virtual Law Viewer ... ten Sonic Foundry MediaSite presentation recorders with the BxVideo ...
Cached Biology Technology:Storytelling makes a comeback in an unlikely place 2Storytelling makes a comeback in an unlikely place 3UW Hospital and Clinics install smart intravenous pumps 2UW Hospital and Clinics install smart intravenous pumps 3Streaming video could make courtrooms into Internet conference calls 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... promising new class of drug designed to target the ... system, some of the HCV strains being treated exhibited ... team of Florida State University biologists, chemists and biomedical ... identify the drug-resistant HCV strains and the molecular-level mechanisms ...
... powerful new ability to engineer the flavor and aroma of ... publishing the most comprehensive deciphering of the beer,s "proteome" ever ... that make beer "beer") appears in ACS, monthly Journal ... say they were inspired to do the research by a ...
... has "significant" potential for preventing cardiomyopathy, a form of heart ... with diabetes, scientists have concluded in a new study. Their ... high risk for diabetic cardiomyopathy, appears in ACS, bi-weekly ... and colleagues note that people with diabetes have at least ...
Cached Biology News:Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
...
... Immunogen: Partially purified chicken ... detects vitamin D receptor (VDR) from ... and fish tissues. This antibody ... glucocorticoid receptors. MA1-710 detects both ...
... AccuPrime™ Pfx DNA Polymerase is ideal ... for downstream applications such as cloning ... provided by a proprietary enzyme preparation ... sp. with proofreading (3'Cut Site5' exonuclease) ...
... The BV-10 offers precision beveling ... and 50m. The unique abrasive ... free for greater control of ... be accomplished very rapidly and ...
Biology Products: